Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends
Inflammatory Bowel Diseases · 12.05.2025 · 31 (5) · 1334-1343
DOI: 10.1093/ibd/izae176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 10.08.2024. Verfasst von Yun Qiu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Machine Learning, Gastrointestinal Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Key R&D Program of China, Key-Area Research and Development Program of Guangdong Province.
Abstract (Originalsprache)
Background
Achieving long-term clinical remission in Crohn’s disease (CD) with antitumor necrosis factor α (anti-TNF-α) agents remains challenging.
Aims
This study aims to establish a prediction model based on patients’ clinical characteristics using a machine-learning approach to predict the long-term efficacy of infliximab (IFX).
Methods
Three cohorts comprising 746 patients with CD were included from 3 inflammatory bowel disease (IBD) centers between June 2013 and January 2022. Clinical records were collected from baseline, 14-, 30-, and 52-week post-IFX treatment. Three machine-learning approaches were employed to develop predictive models based on 23 baseline predictors. The SHapley Additive exPlanations (SHAP) algorithm was used to dissect underlying predictors, and latent class mixed model (LCMM) was applied for trajectory analysis of the longitudinal change of blood routine tests along with long-term IFX therapy.
Results
The XGBoost model exhibited the best discrimination between long-term responders and nonresponders. In the internal training and testing set, the model achieved an AUC of 0.91 (95% CI, 0.86-0.95) and 0.71 (95% CI, 0.66-0.87), respectively. Moreover, it achieved a moderate predictive performance in the independent external cohort, with an AUC of 0.68 (95% CI, 0.59-0.77). The SHAP algorithm revealed disease-relevant laboratory measurements, notably hemoglobin (HB), white blood cells (WBC), erythrocyte sedimentation rate (ESR), albumin (ALB), and platelets (PLT), alongside age at diagnosis and the Montreal classification, as the most influential predictors. Furthermore, 2 distinct patient clusters based on dynamic laboratory tests were identified for monitoring the long-term remission.
Conclusions
The established prediction model demonstrated remarkable discriminatory power in distinguishing long-term responders from nonresponders to IFX therapy. The identification of distinct patient clusters further emphasizes the need for tailored therapeutic approaches in CD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- The Translational Medicine Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology, Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, China.
ORCID-Profile: Shixian Hu, Fengyuan Su, Xiang Gao, Minhu Chen
Förderung
- National Key R&D Program of China
- Key-Area Research and Development Program of Guangdong Province
Zitieren
APA
Qiu, Y., Hu, S., Chao, K., Huang, L., Huang, Z., Mao, R., Su, F., Zhang, C., Lin, X., Cao, Q., Gao, X., & Chen, M. (2025). Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends. Inflammatory Bowel Diseases, 31(5), 1334-1343. https://doi.org/10.1093/ibd/izae176
Vancouver
Qiu Y, Hu S, Chao K, Huang L, Huang Z, Mao R, et al. Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends. Inflammatory Bowel Diseases. 2025;31(5):1334-1343. doi:10.1093/ibd/izae176
BibTeX
@article{Qiu2025,
author = {Qiu, Yun and Hu, Shixian and Chao, Kang and Huang, Lingjie and Huang, Zicheng and Mao, Ren and Su, Fengyuan and Zhang, Chuhan and Lin, Xiaoqing and Cao, Qian and Gao, Xiang and Chen, Minhu},
title = {Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends},
journal = {Inflammatory Bowel Diseases},
year = {2025},
volume = {31},
number = {5},
pages = {1334--1343},
doi = {10.1093/ibd/izae176}
}
EUVIMED